New mRNA shingles vaccine shows promise in Mid-Stage trial
NCT ID NCT07285278
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests a new mRNA vaccine (ABO1108) to see if it can safely prevent shingles in adults aged 40 and older. About 300 healthy volunteers or those with stable health conditions will receive two shots, two months apart. Researchers will measure the body's immune response and watch for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuzhou, China
Conditions
Explore the condition pages connected to this study.